Group Leader PKPD, Principal Scientist II
Curtis joined Metrum in 2014 after receiving his Pharm.D. from the University at Buffalo and completing a clinical PK/PD Fellowship through UNC Chapel Hill/Quintiles. His clinical experience includes infectious disease (bacterial), oncology, and chronic liver disease (HCV and NASH). Curtis’s research interests include Bayesian methodology and the application of M&S to help inform drug development decisions.
July 31, 2023
DINAMO showed that an empagliflozin dosing regimen provided clinically and statistically meaningful reductions in HbA1c in youth with T2D. Bayesian Borrowing analysis confirmed evidence for clinically meaningful efficacy of empagliflozin
October 28, 2022
Katherine Kay, Kyle Baron, Seth Green, Samuel Callisto, Curtis Johnston, Kyle Barrett, Devin Pastoor, Jim Rogers, Ana Ruiz-Garcia, Tim Waterhouse, Matthew Wiens, Matthew Riggs. Poster presented at 2022 American Conference on Pharmacometrics (ACoP13). 30 October – November 2 2022. Poster M-062
June 24, 2021
John T. Mondick and Curtis K. Johnston. Webinar presented for American Society for Clinical Pharmacology and Therapeutics (ASCPT). June 22, 2021.